Nautilus Biotechnology

Nautilus Biotechnology is a Seattle company that wants to identify and count proteins one molecule at a time. It was incorporated in 2016 and has been listed on Nasdaq as NAUT since June 9, 2021. Its annual report filed on February 26, 2026 says that it has no product for sale and has earned no revenue from its platform.^[1]

A Nautilus flow cell carries a chip whose surface has sites that the company calls landing pads, more than 3 billion to a chip. A protein cannot be placed on a pad directly, so each one is first attached to a nanoparticle scaffold built to carry exactly one protein, and the pads are sized to take exactly one scaffold. Pour the mixture over the chip and the molecules sort themselves into a grid, one to a site.^[1]

Every protein then has an address. In each cycle a labeled reagent that binds some proteins and not others flows across the chip, a camera records which addresses light up, and the next reagent follows. A record of what bound each address builds up, and software reads the record as an identity; the report describes this analysis as running on "10 billion protein molecules captured across three flow cells in parallel".^[1] Amino acids are never read in order, as they would be in protein sequencing.

Holding the molecules in place is the point of the design. A method such as ELISA makes one measurement of a sample, the report says, "after which the sample is either damaged, destroyed or discarded", whereas proteins on the chip can be probed again, and the company calls the method Iterative Mapping.^[1]

The human genome encodes about 20,000 canonical proteins. The report says they give rise to millions of proteoforms, variants of one protein that differ in modifications such as an added phosphate group, and that bulk methods blur those variants together.^[1][a] The first application is tau, a protein associated with Alzheimer's disease: a targeted assay that uses ordinary, highly specific reagents to count the proteoforms of tau. A broadscale assay, built on reagents that the company has made to bind many proteins, is planned to follow.^[1]

Two founders are named in the company's reports: Sujal Patel, now chief executive, and Parag Mallick, chief scientist.^[1] The company became public through a business combination with ARYA Sciences Acquisition Corp III, a special-purpose acquisition company, which closed on June 9, 2021 and gave the merged company its name.^[1]

The reports for 2021 and 2023 call the product the "Nautilus platform" and describe a "proteome analysis system", an integrated fluidics and optics system for "massively parallel single protein molecule detection", to be launched in three phases.^[2][3] By the report for 2025 the instrument is the Nautilus Voyager and the method is Iterative Mapping.^[1]

An Iterative Mapping Early Access Program began in January 2026, in which customers send samples for analysis, starting with the tau assay. The company does not anticipate that the program "will result in any material revenue", and says it expects to take pre-orders for the Voyager from late 2026.^[1]

The incumbents it names are mass spectrometry and affinity methods such as ELISA.^[1] Other single-molecule efforts read protein differently: Quantum-Si identifies peptides by fluorescence on a semiconductor chip, and the groups in Nanopore protein sequencing read the ionic current of a protein passing through a pore.

• Glyphic Biotechnologies
• List of nanopore companies
• Nanopore protein sequencing
• Protein sequencing
• Quantum-Si